DIAN-TUNCT05269394
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 11 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 20 words Show 4 more changesShow less
- Trial sites reduced: 36 → 31 locations
- Secondary endpoints: details revised at 3 of 7 entries
- Collaborators: details revised at 1 of 4 entries
- Publications: details revised at 12 of 12 entries
- Minor Study sites revised (36)v11
- Minor Study sites: 38 to 36v10
- Minor Site details revised at 3 of 38 sitesv9
Notable Primary completion date: Jul 2027 to Apr 2028v7 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 168 to confirmed 197
- Study completion date: Oct 2027 to Jul 2028
- Site details revised at 38 of 38 sites
Show 5 earlier versionsHide 5 earlier versions
- Minor Study sites: 39 to 38v6
- Minor Site details revised at 2 of 39 sitesv5
- Minor Site details revised at 4 of 39 sitesv4
- Minor Study sites: 40 to 39v3
- Minor Site details revised at 4 of 40 sitesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Symptomatic Population (Cohort 1) At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period. At Week 24, participants randomized to E2814 will receive intravenously in a blinded fashion for the remainder of their treatment period. Asymptomatic Population (Cohort 2) At Week 0, participants randomized to E2814 will receive intravenously in a blinded fashion for the full treatment period. At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period.
Symptomatic Population (Cohort 1) At Week 0, participants will receive open-label lecanemab administered intravenously for the full treatment period. At Week 24, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the remainder of their treatment period. Asymptomatic Population (Cohort 2) At Week 0, participants randomized to E2814 placebo will receive placebo intravenously in a blinded fashion for the full treatment period. At Week 52, all participants will initiate open-label lecanemab administered intravenously for the remainder of their treatment period.
Drugs: E2814, Lecanemab, Matching Placebo (E2814)
Sites
31 sites in 15 countries
United States 12, Canada 3, Australia 2, Germany 2, Italy 2, Argentina 1, Brazil 1, Colombia 1, Ireland 1, Japan 1, Mexico 1, Netherlands 1, Puerto Rico 1, Spain 1, United Kingdom 1